Payment overview · 2025
General Payments
$893.97
49 reported records · 14 companies
Healthcare provider profile · identity verified
Kathryn Poole
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PAOLI, IN · NPI 1689154452
Verified facts
What the public records show
CMS Open Payments records show Kathryn Poole received $893.97 in general payments during 2025 across 49 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $269.38 | 30.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.24 | 17.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.88 | 15.7% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.55 | 9.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.81 | 5.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.32 | 5.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.87 | 4.6% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.77 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.11 | 1.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.32 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.10 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.60 | 1.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.54 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.48 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $893.97 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $211.98 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $179.62 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $152.46 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.76 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.92 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.81 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $110.58 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.55 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $45.32 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $45.32 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.69 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.48 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 40 |
| Lisinopril | Lisinopril | 174 | 38 |
| Gabapentin | Gabapentin | 120 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 17 |
| Mounjaro | Tirzepatide | 114 | 18 |
| Metformin Hcl | Metformin Hcl | 107 | 26 |
| Omeprazole | Omeprazole | 105 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 101 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 22 |
| Meloxicam | Meloxicam | 83 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 22 |
| Metformin Hcl Er | Metformin Hcl | 78 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 16 |
| Clonazepam | Clonazepam | 71 | 12 |
| Farxiga | Dapagliflozin Propanediol | 71 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 17 |
| Losartan Potassium | Losartan Potassium | 66 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 12 |
| Tramadol Hcl | Tramadol Hcl | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Simvastatin | Simvastatin | 42 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 12 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Furosemide | Furosemide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Diazepam | Diazepam | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $893.97 · 49 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ARISTADA, BREZTRI, CAPLYTA, CAPVAXIVE, ENFLONSIA, FARXIGA, GARDASIL 9, Jornay PM, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROQUAD, QULIPTA, REPATHA, ROTATEQ, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VRAYLAR, VYEPTI, Wegovy, ZEPBOUND, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error